Extended aromatase inhibitor therapy reduces breast cancer recurrence in postmenopausal women
1. Invasive breast cancer recurrence was significantly reduced with extended aromatase inhibitor therapy. 2. No significant reduction was noted for ...
Tag: aromatase inhibitor
Alternative Dose Regimens of Exemestane in Postmenopausal Women with Breast Cancer
1. Through the reduction in serum estradiol, there was noninferiority between the 3-times-weekly vs once-daily dosage among compliant participants (PP ...
#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
Click to read this study in The Lancet Oncology.
#VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer
Click to read this study in The Lancet Oncology.
#VisualAbstract: Maintenance endocrine therapy plus bevacizumab after induction with paclitaxel is effective for ER+ breast cancers
Click to read this study in The Lancet Oncology.
#VisualAbstract: Concurrent use of tamoxifen with direct oral anticoagulants is not associated with an increased risk of hemorrhage
Click to read this study in JAMA Network Open.
#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in premenopausal women with ER+ breast cancer and ovarian suppression
Click to read this study in The Lancet Oncology.
Two-year anastrozole treatment beneficial for disease-free survival in postmenopausal breast cancer
1. A five-year extension of anastrozole treatment was shown not to provide additional benefit compared to a two-year extension in ...
#VisualAbstract: Aromatase inhibitors superior to tamoxifen for progression-free survival in HR⁺ advanced breast cancer
Click to read the study in the European Journal of Cancer.
Additional aromatase inhibitor may improve endometrial cancer chemotherapy effectiveness
1. In a phase II trial of 35 women with advanced endometrial cancer, combination therapy with aromatase inhibitor (letrozole) and ...
